Oramed Pharmaceuticals to Present at the 70th Scientific Sessions of the American Diabetes Association
JERUSALEM, June 28, 2010/PRNewswire-FirstCall/ --
- Results of First Exposure of Type I Diabetes Patients to
Oramed's Oral Insulin and of a First-in-Humans Study With its Oral
GLP-1 Analog
Oramed Pharmaceuticals, Inc. (OTCBB: ORMP) announced today that
its executive management is participating in the 2010 Scientific
Sessions of the American Diabetes Association currently being held
in Orlando, Florida. Dr. Miriam Kidron, Chief Scientific Officer,
is scheduled to present results of two of the company's recently
completed clinical trials between 12:00 - 2:00 PM ET on Monday,
June 28, 2010 in Poster Hall C at the Orange County Convention
Center.
One presentation will provide an overview of the results of a
Phase IIa study testing the company's flagship ORMD-0801 oral
insulin capsule in Type I diabetes patients when administered just
before (10-90 minutes) a standard meal. This first exposure of
Oramed's oral insulin established the drug's safety and efficacy in
Type I diabetics. ORMD-0801 led to a significant increase in
insulin levels in 61% of the treatment sessions, irrespective of
the time lapse between ORMD-0801 administration and mealtime. The
oral insulin preparation effectively kept glucose levels in check
in all sessions. These data suggest both tolerance of Oramed's
platform to preprandial dosing regimens and its therapeutic
potential in regulating Type I diabetes.
In addition, Dr. Kidron will present a summary of Oramed's
first-in-humans clinical trial testing the safety and efficacy of
ORMD-0901, an encapsulated oral GLP-1 analog formulation. The study
monitored the responses of healthy males to a single dose delivered
60 minutes before a glucose load. ORMD-0901 was well tolerated by
all subjects and demonstrated physiological activity, as
extrapolated from ensuing subject insulin levels when compared to
those observed after treatment with placebo.
The poster entitled "Oral Insulin: Type I Diabetes (T1DM)
Patient Response Upon Preprandial Administration" will be featured
in a guided tour in the Poster Hall. The tour title is "Innovations
in Novel Insulin Preparations" and is scheduled for Monday June 28
at 12:00-1:00 PM.
To view the posters being presented, please visit:
http://www.oramed.com
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a technology pioneer in the field of
oral delivery solutions for drugs and vaccines presently delivered
via injection. Oramed is seeking to revolutionize the treatment of
diabetes through its patented flagship product, an orally
ingestible insulin capsule currently in Phase 2 clinical trials.
Established in 2006, Oramed's technology is based on over 25 years
of research performed by top research scientists at Jerusalem's
Hadassah Medical Center. The Company's corporate and R&D
headquarters are based in Jerusalem.
For more information, please visit http://www.oramed.com.
Safe Harbor Statement
Some of the statements contained in this press release are
forward-looking statements which involve known and unknown risks,
uncertainties and other factors which may cause the actual results,
performance or achievements of the company, or industry results, to
be materially different from any future results, performance or
achievements expressed or implied by such forward looking
statements, including the risks and uncertainties related to the
progress, timing, cost, and results of clinical trials and product
development programs; difficulties or delays in obtaining
regulatory approval for our product candidates; competition from
other pharmaceutical or biotechnology companies; and the company's
ability to obtain additional funding required to conduct its
research, development and commercialization activities. Please
refer to the company's filings with the Securities and Exchange
Commission for a comprehensive list of risk factors that could
cause actual results, performance or achievements of the company to
differ materially from those expressed or implied in such forward
looking statements. The company undertakes no obligation to update
or revise any forward-looking statements.
Company and Investor Relation Contacts:
Oramed Pharmaceuticals Inc.
Tara Horn
Office: +1-646-240-4193
Cell: +972-54-334-4318
Email: tara@oramed.com
Source: Oramed Pharmaceuticals Inc.
Company and Investor Relation Contacts: Oramed Pharmaceuticals
Inc., Tara Horn, Office: +1-646-240-4193, Cell: +972-54-334-4318,
Email: tara@oramed.com .
Posted: June 2010
